DLBCLs show different patterns of P16 expression. High levels of P16 may mitigate tumour cell proliferation. Gains of p16 do not necessarily increase P16 protein expression.
Introduction
Progression of cell cycle is tightly controlled at multiple checkpoints to ensure normal cell proliferation. Passage through each checkpoint is regulated by a series of cyclins, cyclin-dependent kinases (CDK) and CDK inhibitors [1] . p16 (also known as CDKN2A, MTS1 or INK4A ) is a tumour suppressor gene that resides in the 9p21 chromosomal region [1, 2] . Expression of p16 has first been discovered as a 16-kDa protein that binds exclusively to CDK4 and CDK6 [3] . In the proliferative state, CDK4 and CDK6 are activated by cyclin D to phosphorylate the PRb. Phosphorylated PRb releases E2F, a transcription factor responsible for cell cycle transition from G 1 to S phase. Binding of P16 to CDK4 and CDK6 may inhibit phosphorylation of PRb and induce cell growth arrest at the G 1 checkpoint [1, 2] . There is controversy concerning the expression of P16 in carcinogenesis. Loss of P16 as a result of genetic inactivation has been a common event in tumour cell lines and primary tumours [2, 4] . However, varying results have been reported in the past decade, suggesting a prevalence of P16 overexpression in human neoplasms [5] [6] [7] [8] .
Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid malignancy comprising several disease subentities [9] . Based on cell origin, gene expression profiling using cDNA microarrays has identified three distinct subgroups of DLBCL: (1) the germinal centre B-cell-like (GCB) subgroup, with features of GCB cells, (2) the activated B-cell-like and type 3 subgroups, with features of post-GCB cells [10, 11] , and (3) primary mediastinal B cell lymphoma (PMBL), with features of thymic B cells [12] . It was claimed that it is possible to identify DLBCL subgroups similar to those of cDNA microarrays by immunohistochemical analysis using a panel of antibodies [13] . In immunohistochemical analysis, expression of CD10 and BCL-6 is used to define the GCB phenotype whereas expression of MUM-1 is related to the non-GCB phenotype [13] . The GCB phenotypic subgroup is known as a predictor of a favourable outcome, while the non-GCB phenotypic subgroup appears to predict an unfavourable outcome [10, 13] .
GCB and non-GCB DLBCLs may develop through different oncogenic pathways [14] and express differential levels of cell cycle regulators [15] . Loss of P16 in DLBCL has been studied by different research groups [15, 16] and has been shown to associate with the non-GCB phenotype [15] . In order to further elucidate the role of p16 in lymphomagenesis, we investigated P16 overexpression in de novo DLBCL by immunohistochemistry in order to clarify the sites of presentation, immunophenotypic subgroups and proliferation profiles as denoted by the expression of Ki-67. FISH was employed to analyse genetic alterations of p16 and their associations with high levels of P16 protein in DLBCL.
Materials and Methods

Tissue Samples
A total of 70 formalin-fixed, paraffin-embedded specimens from DLBCL cases (34 nodal and 36 extranodal) obtained between the years 1996 and 2006 were retrieved from the archives of a single institution. All cases were reconfirmed as DLBCL based on the criteria of the WHO classification of haematopoietic and lymphoid tissue tumours [9] . One patient had DLBCL with features of classical Hodgkin lymphoma. Colon carcinoma and reactive hyperplastic lymphoid tissues, including lymph nodes and tonsils, were used as controls.
Immunohistochemistry
The Envision system was employed for the staining of CD10, BCL-6 and MUM-1. The avidin-biotin complex system was employed for the staining of P16 and Ki-67. Three-micrometer-thick sections were cut from paraffin-embedded tissue blocks, deparaffinised in xylene and dehydrated through a graded ethanol series. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in methanol. Heat-induced antigen retrieval was achieved by pressure cooking. After cooling to room temperature, antigen-retrieved sections were incubated with primary antibodies. Reactions against CD10 (1: 50; clone 56C6, Novocastra Laboratories, UK), BCL-6 (1: 10; clone PG-B6p, DakoCytomation, Denmark), MUM-1 (1: 25; clone MUM1p, DakoCytomation) and Ki-67 (1: 50; clone MIB-1, DakoCytomation) were run for 2 h at room temperature; overnight incubation at 4 ° C was performed for P16 (1: 200; clone 16P07, Neomarkers, USA). Chromogenic development of all staining was achieved using diaminobenzidine (DakoCytomation). Haematoxylin was used as nuclear counterstain. External positive controls, i.e. reactive lymphoid tissues for staining of CD10, BCL-6, MUM-1 and Ki-67, and colon carcinoma for staining of P16 were included in every run of the assay.
All stained slides were evaluated by a pathologist (S.C.P.) blinded to the clinicopathological data and FISH results. The percentages of tumour cells showing protein immunoreactivity were determined visually. CD10 was considered to be expressed when 6 30% of tumour cells showed membrane staining. BCL-6 and MUM-1 were considered to be expressed when 6 30% of tumour cells showed nuclear staining. The Ki-67 indices (percentages of cells expressing Ki-67) were stratified into five groups based on the extent of protein immunoreactivity: (1) ! 10% of positive tumour cells, (2) 10-25% of positive tumour cells, (3) 26-50% of positive tumour cells, (4) 51-75% of positive tumour cells, and (5) 1 75% of positive tumour cells. Staining was regarded as inconclusive if immunoreactivity was not observed in the internal positive controls, i.e. fibroblasts and neutrophils for CD10, and reactive lymphocytes for BCL-6, MUM-1 and Ki-67. The algorithm proposed by Hans et al. [13] , based on CD10, BCL-6 and MUM-1 expression, was employed to stratify all the DLBCL cases into GCB and non-GCB phenotypic subgroups ( fig. 1 ).
P16 expression was separately classified into three categories: (1) simultaneous nuclear-cytoplasmic staining, (2) purely cytoplasmic staining, and (3) purely nuclear staining. Both the intensity and extent of staining were considered during the evaluation. Staining intensity was scored as follows: 1+ as weak, 2+ as moderate, and 3+ as strong. The extent of staining was graded as the percentage of positively stained tumour cells. Cut-off points for increased P16 expression were derived from seven reactive hyper- 
Fluorescence in situ Hybridization
Interphase FISH analysis was performed using a commercially available dual-colour probe consisting of locus-specific identifier (SpectrumOrange) and centromere enumeration probe 9 (SpectrumGreen) (Abbott Molecular Inc., USA). Locus-specific identifier p16 spans approximately 190 kb and hybridizes to the 9p21 chromosomal region, containing the following genetic loci D9S1749, D9S1747, p16 , p14 , D9S1748, p15 and D9S1752. Centromere enumeration probe 9 is a chromosome 9 control probe designed to detect the ␣ -satellite sequences 9p11-q11. The FISH assay was performed as previously described [17] . A reactive lymphoid tissue section was incorporated in every run of the assay as experimental control.
All FISH specimens were evaluated using a fluorescence microscope equipped with appropriate filter cubes. Specimens were scanned using a 40 ! objective to identify the tumour areas. Digital images of the tumour areas were acquired using an integrating monochrome CCD camera and a 100 ! objective. At least 190-210 intact and non-overlapping nuclei were scored for the copy numbers of p16 (visualized as red signal) and chromosome 9 (visualized as green signal). Only nuclei with at least 1 green signal were enumerated. The scoring system was based on the percentage of nuclei showing different copy numbers of p16 and chromosome 9. An additional slide was prepared for specimens with less than 190 evaluated nuclei. Cases were considered noninformative if the supplemental slide failed to yield sufficient nuclei for analysis. Cases with poor signal intensity and/or excessive background autofluorescence were also regarded as non-informative.
Cut-off values for p16 alterations were determined from 15 normal controls (reactive hyperplastic lymphoid tissues) based on the mean percentages of normal cells exhibiting altered signals and dispersions (as defined by standard deviations) of the incidence values ( table 1 ). All established cut-off values were verified in terms of specificity and sensitivity using receiver operating characteristic curve analysis. Thresholds with 100% specificity were considered. Cases with altered signals exceeding the corresponding cut-off values were interpreted as alterations of p16 .
Statistical Analysis
Pearson's 2 and Fisher's exact probability tests were used to examine the relationships between the different investigated parameters. The Mann-Whitney U test was employed to determine the differences in the frequencies of p16 alterations between normal controls and DLBCL. The results were considered statistically significant when p ! 0.05. SPSS for Windows, version 13 (SPSS Inc., USA) was used to perform all statistical analysis.
Results
Patient Data
The DLBCL series included 38 (54.3%) male and 32 (45.7%) female patients. The mean age of these patients at the time of diagnosis was 52.4 8 16.5 years (median, 53.5 years; range, 3-86 years). 40.0% (28/70) of patients were aged 50 years or less. The studied subjects were comprised of three ethnic groups: Chinese (33/70, 47.1%), Malay (28/70, 40.0%) and Indian (9/70, 12.9%). The clinicopathological features of each patient are presented in table 2 .
Immunophenotypic Profiles
Of all the DLBCL cases, 32.9% (23/70) exhibited positive CD10 expression, 62.9% (44/70) expressed BCL-6 and 71.4% (50/70) demonstrated positive MUM-1 expression. 38.6% (27/70) of the cases were assigned to the GCB subgroup, and 61.4% (43/70) to the non-GCB subgroup ( fig. 1 ) .
Proliferation Profiles
The cell proliferation marker Ki-67 was expressed in all (100%) DLBCL cases; positivity ranged from 10 to 1 75%. No cases had Ki-67 indices ! 10%. Ki-67 indices of 10-25, 26-50 and 51-75% were noted in 11.4% (8/70), 21.4% (15/70) and 22.9% (16/70) of the cases, respectively. The majority (31/70; 44.3%) of the cases showed strong Ki-67 expression with indices higher than 75%.
Expression of P16
P16 expression was interpretable in all (100%) DLBCL cases. Overall, 45.7% (32/70) of the cases showed P16 overexpression. High levels of P16 were observed predominantly as simultaneous nuclear-cytoplasmic staining (29/32; 90.6%) as shown in figure 2 a or purely cytoplasmic staining (3/32; 9.4%). P16 overexpression and CD10 positivity (p = 0.022) were significantly associated. Increased P16 expression was significantly associated with the GCB subgroup (p = 0.022). An inverse correlation was found between P16 overexpression and a high proliferative index (Ki-67 index 1 75%) of tumour cells (p = 0.020). No statistically significant correlations were found between P16 overexpression and sites of presentation (p = 0.826) and expression of BCL-6 (p = 0.152) and MUM-1 (p = 0.129) ( table 3 ).
Alterations of p16
FISH signals were interpretable in 67.1% (47/70) of the DLBCL cases. The Mann-Whitney U test demonstrated that the frequencies of monosomy 9 (p = 0.019), hemizygous p16 deletion (p = 0.002), homozygous p16 deletion (p ! 0.001) and polysomies 9 (p = 0.032) were significantly different between DLBCL cases and normal controls.
There was no significant difference between tumour cases and normal controls in the frequencies of p16 gene amplification (p = 0.771). Monosomy 9 and hemizygous and homozygous deletions were referred to as losses of p16 . Gains of p16 in the present DLBCL series were observed as polysomies 9.
Of the 47 interpretable hybridizations, hemizygous and/or homozygous deletions were evident in 27 (57.4%) cases. The concurrent occurrence of hemizygous and homozygous deletions in individual cases was statistically significant (p = 0.043). Simultaneous hemizygous and homozygous deletions were present in 11 of 27 (40.7%) cases, purely hemizygous p16 deletion was shown in 9 of 27 (33.3%) cases, and purely homozygous deletion was shown in 7 of 27 (25.9%) cases. None of the examined specimens showed monosomy 9. Gains of p16 due to polysomies 9 were noted in 27.7% (13/47) of the cases. Representative examples of DLBCL harbouring cytogenetic alterations are illustrated in figure 2 
p16 deletions were significantly associated with extranodal presentation (p = 0.047). No statistically significant associations or differences were observed in different subgroups of DLBCL relative to p16 deletions (p = 0.137) and p16 gains (p = 0.726). P16 protein overexpression was not significantly associated with gains of p16 gene (p = 0.621), but was inversely related to p16 gene deletions (p = 0.019) ( table 4 ). 
Discussion
There are but few studies on the expression profile and alterations of p16 in DLBCL. In the present study, we found that a large proportion of the DLBCL cases (45.7%) showed overexpression of P16. The frequency is higher than that reported by Møller et al. [18] (17.1%), but is lower than that reported by Jehan et al. [19] , i.e. 72.0%. This discrepancy is most likely due to the differences in sample size and/or variations in the scoring system. In agreement with the findings of Finegan et al. [6] and Melck et al. [7] , overexpression of P16 in the present series was predominantly the result of increased simultaneous nuclearcytoplasmic expression (90.6%). Prior surveys indicated that P16 expression is low or undetectable in the normal physiological state, but may be markedly increased during tumourigenesis [5, 20] . Hence, it is conceivable that DLBCLs without P16 overexpression may be found among those having basal physiological levels of P16. Alternatively, it could be attributed to inactivation of p16 by gene deletion or methylation of the gene promoter region [15, 16, 18] .
We noted in both reactive lymphoid tissues and DLBCL that highly proliferative regions, particularly germinal centres, displayed relatively higher expression of P16 than others. Similar observations were also report- ed by Villuendas et al. [16] . Our findings revealed P16 overexpression and CD10 expression were correlated (p = 0.022). Given that CD10 is a marker of GCB cells [21] , we speculate that increased expression of P16 is related to antigen-dependent germinal centre development, where follicular centre cells are actively proliferating [21] . Overexpression of P16 could be one of the regulatory mechanisms controlling B cell generation and proliferation. In this study, overexpression of P16 was significantly more common in GCB (63.0%) than in non-GCB DLBCLs (34.9%) (p = 0.022). These results further strengthen the notion that GCB and non-GCB subgroups exhibit distinct molecular features and oncogenic events [9, 14] . The prognostic significance of P16 overexpression in non-Hodgkin lymphoma is not apparent, but entities with loss of P16 expression have always been related to an aggressive clinical course [15, 16, 22] . By extrapolation, it is conceivable that high-level P16 may lead to a favourable outcome in DLBCL. Current findings indicating an association of P16 overexpression with GCB DLBCL may support this hypothesis. It was reported that DNA replication stress and oncogene-induced senescence could potentially upregulate P16 expression, leading to a halt in lymphomagenesis [23] . Sandig et al. [24] also showed that ectopic overexpression of P16 may lead to apoptosis as well as cell growth arrest both in vivo and in vitro. On this basis, we suggest the favourable prognosis in the GCB subgroup as reported previously [10, 13] may be related to the role of P16 in inhibiting cell proliferation and inducing apoptosis.
The Ki-67 index has always been considered to reflect the rate of cell proliferation [21] . It was observed in the present study that the majority (75.0%) of the DLBCL cases with high levels of P16 showed Ki-67 indices ^ 75%. The inverse relationship between P16 overexpression and high Ki-67 index ( 1 75%) (p = 0.020) is consistent with the role of P16 as a cell cycle inhibitor [1, 2] . In contrast to our results, an investigation in breast cancer showed a parallel relationship (p = 0.005) between strong expression of P16 and a high Ki-67 index ( 1 50%) [8] . The reasons for these discordant results await elucidation. Expression of P16 [reviewed in 1 ] and Ki-67 [25] may fluctuate at different levels along the cell cycle. P16 appears to be more accentuated at the G 1 /S transition [reviewed in 1 ], whereas Ki-67 expression seems to peak at the G 2 /M transition [25] . In support of these findings, it is speculated that increased expression of P16 may be an early event in the cell cycle and may mitigate proliferation of tumour cells.
There was no significant association between overexpression of P16 and site of presentation, although it was previously shown that P16 upregulation was more prevalent in extranodal DLBCLs [19] . In agreement with our data, Paik et al. [15] showed no significant difference in the expression of P16 between nodal and extranodal DLBCLs. The reasons for these discordant results are not clear.
In our DLBCL series, losses of p16 were typically detected as deletions of one allele (hemizygous deletion) and/or deletion of both alleles (homozygous deletion). Chromosomal loss (monosomy 9) was not observed in any cases even though it has been reported as an underly- [18, 22, [27] [28] [29] . The variability of the data could be linked to differences in techniques of analysis, hence variations in the sensitivity and specificity of detection [1, 4] . Current publications agree that FISH is a more sensitive and precise method in detecting gene deletions than multiplex PCR and Southern blot analysis [4, 30] . Since FISH allows cell-by-cell assessment, we are able to perform analyses without contaminating normal cells [30] . This might also explain the higher rate of deletions in our series than in studies performed using comparative genomic hybridization: 15.3% in Lenz et al. [28] and 52.2% in Tagawa et al. [29] .
In the subset showing p16 deletions, 40.7% (11/27) of the cases were found to harbour simultaneous hemizygous and homozygous deletions, suggesting that partial loss and complete loss of p16 alleles are significantly interrelated (p = 0.043). Our observation confirms that of Cairns et al. [4] , who reported high frequencies of homozygous p16 deletion in various primary tumours showing loss of heterozygosity at 9p21. It is conceivable that tumour cells with partial loss of p16 may have an increased life span and genomic instability, thus predisposing the remaining allele to undergo deletion; tumour cells with biallelic deletion of p16 are most probably derived from entities harbouring loss of heterozygosity [1] . On the other hand, Konemann et al. [31] revealed that human neoplasms may comprise different populations of tumour cells, and each population may display distinct clonality and genetic features. The simultaneous occurrence of hemizygous and homozygous p16 deletions may explain the clonal and molecular heterogeneity in DLBCL [9, 31, 32] . The presence of neoplastic cells with a distinct heterogeneous molecular background in a single sample may reflect a process of tumour progression [32] .
In the present study, the frequency of p16 deletions was higher in extranodal DLBCLs (16/22; 72.7%) than in nodal DLBCLs (11/25; 44.0%) (p = 0.047). This observation reinforces the notion that DLBCLs arising in extranodal sites harbour genetic alterations that differ from those in the lymph nodes [33] .
Gains of p16 were detected in 27.7% (13/47) of the DLBCL cases. Notably, p16 gains in our series were associated with chromosomal duplication (polysomies 9) rather than p16 gene amplification. This finding is in concordance with earlier reports that gene amplification is rarely detected in lymphoma [34, 35] . Previous studies reported that gains in the 9p21 chromosomal region involving p16 loci are a characteristic of PMBL [36, 37] . In the absence of gene expression profiles, we were not able to decide whether the DLBCL cases with extra copies of p16 were cases of PMBL.
It appeared in this study that P16 overexpression was not attributed to gains of p16 gene (p = 0.621). Indeed, gains of a gene do not necessarily lead to protein overexpression since the overrepresented genes can potentially be silenced by genetic alterations such as point mutations and promoter methylation [38] . Our data revealed an inverse relationship between P16 overexpression and gene deletions (p = 0.019), compatible with the notion that protein expression and gene inactivation are mutually exclusive [16, 18] . Finegan et al. [6] suggested the high level of P16 could be attributed to accumulation of mutant protein with extended half-life. It has been revealed in prostate cancer that P16 overexpression should be attributed to upregulation of p16 [5] by different molecular mechanisms, including lack of functional PRb [reviewed in 1 ], overexpression of cyclin D and/or CDK4 [5] and cellular senescence [23] . Further studies are needed to clarify the involvement of these mechanisms in P16 overexpression in DLBCL.
In conclusion, our study provides evidence that P16 overexpression is common in DLBCL. The level of P16 expression may differ between GCB and non-GCB subgroups. Increased expression of P16 may mitigate cell proliferation and potentially lead to cell growth arrest. Losses of p16 are attributed to p16 gene deletions rather than monosomy 9, and gains of p16 are associated with polysomies 9 rather than p16 gene amplification. Deletions of p16, including hemizygous and homozygous deletions, are more common than gains of p16 , and overexpression of P16 protein is not associated with gains of p16 gene. Further investigations on cellular signalling and molecular mechanisms responsible for P16 overexpression may provide further insight into the importance of p16 in the development of DLBCL.
